EMA Authorised: Ulunar Breezhaler (glycopyrronium bromide;indacaterol maleate) — Novartis Europharm Limited

View source ↗

Summary

The EMA authorised Ulunar Breezhaler, a fixed-dose inhalation combination of glycopyrronium bromide and indacaterol maleate, for chronic obstructive pulmonary d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Ulunar Breezhaler (glycopyrronium bromide; indacaterol maleate)

Snippet

Status: Authorised. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: Novartis Europharm Limited. Decision date: 24/07/2025